Johnson & Johnson Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
Johnson & Johnson (JNJ) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 12.37 million shares for the 12-month period ending 2025-12-28, per its 10-K filed 2026-02-11.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2026-02-11
- Johnson & Johnson share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2025 was 12.37M shares, a 11.14% decline from fiscal 2024.
- Johnson & Johnson share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2024 was 13.92M shares, a 14.72% decline from fiscal 2023.
- Johnson & Johnson share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2023 was 16.32M shares, a 17.61% decline from fiscal 2023.
- Johnson & Johnson share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2023 was 19.81M shares, a 6.93% increase from fiscal 2022.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month as first filed |
|---|---|---|
| 2025-12-28 | 12.37M shares 10-K · filed 2026-02-11 | |
| 2024-12-29 | 13.92M shares 10-K · filed 2025-02-13 | |
| 2023-12-31 | 16.32M shares 10-K · filed 2024-02-16 | |
| 2023-01-01 | 19.81M shares 10-K · filed 2023-02-16 | |
| 2022-01-02 | 18.52M shares 10-K · filed 2023-02-16 | |
| 2021-01-03 | 20.72M shares 10-K · filed 2023-02-16 | |
| 2019-12-29 | 19.75M shares 10-K · filed 2022-02-17 | |
| 2018-12-30 | 17.11M shares 10-K · filed 2021-02-22 | |
| 2017-12-31 | 19.29M shares 10-K · filed 2020-02-18 | |
| 2017-01-01 | 22.49M shares 10-K · filed 2019-02-20 | |
| 2016-01-03 | 20.48M shares 10-K · filed 2018-02-21 | |
| 2014-12-28 | 24.36M shares 10-K · filed 2017-02-27 | |
| 2013-12-29 | 29.01M shares 10-K · filed 2016-02-24 | |
| 2012-12-30 | 8.66M shares 10-K · filed 2015-02-24 | |
| 2012-01-01 | 9.53M shares 10-K · filed 2014-02-21 | 9.53K shares 10-K · filed 2012-02-23 |
| 2011-01-02 | 14.00M shares 10-K · filed 2013-02-22 | |
| 2010-01-03 | 21.58K shares 10-K · filed 2012-02-23 | 21.58M shares 10-K · filed 2011-02-25 |
| 2008-12-28 | 22.43M shares 10-K · filed 2011-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |